Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | -0.29% | +56.45% | +107.18% | 54.92B | |
| -1.22% | +2.25% | +43.78% | +38.45% | 44.31B | |
| +0.19% | +5.19% | -14.43% | -19.16% | 22.96B | |
| -2.64% | -4.39% | -6.79% | +373.48% | 21.12B | |
| -2.91% | -1.18% | +7.21% | -36.53% | 16.31B | |
| -2.38% | -3.38% | +5.53% | -41.88% | 15.19B | |
| -0.87% | -0.74% | +25.98% | +175.52% | 13.32B | |
| +1.48% | +11.36% | +22.59% | - | 12.48B | |
| +4.10% | +7.02% | +104.41% | +226.33% | 11.21B | |
| Average | -0.56% | +2.67% | +27.19% | +102.92% | 23.54B | |
| Weighted average by Cap. | -0.83% | +2.01% | +31.00% | +93.72% |
